| Literature DB >> 26797191 |
Lhassane Ismaili1, Bernard Refouvelet2, Mohamed Benchekroun2, Simone Brogi3, Margherita Brindisi3, Sandra Gemma3, Giuseppe Campiani3, Slavica Filipic4, Danica Agbaba4, Gerard Esteban5, Mercedes Unzeta5, Katarina Nikolic6, Stefania Butini7, José Marco-Contelles8.
Abstract
Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, β-amyloid fibril deposition, and β-amyloid oligomers formation. Based on the involvement of a relevant number of biological systems in Alzheimer's disease progression, multitarget compounds may enable therapeutic efficacy. Accordingly, compounds possessing, besides anticholinergic activity and β-amyloid aggregation inhibition properties, metal chelating and/or nitric oxide releasing properties with additional antioxidant capacity were developed. Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. The purpose of this review will be to highlight recent reports on the development of multitarget compounds for Alzheimer's disease published within the last years focusing on multifunctional ligands characterized by tacrine-like and donepezil-like structures.Entities:
Keywords: Acetylcholinesterase; Alzheimer's disease; Beta secretase; Butyrylcholinesterase; Cholinesterases; Histamine receptor; Monoamine oxidases; Multi-target-directed ligand; Nitric oxide; Reactive oxygen species; Serotonin receptors; β-Amyloid
Mesh:
Substances:
Year: 2016 PMID: 26797191 DOI: 10.1016/j.pneurobio.2015.12.003
Source DB: PubMed Journal: Prog Neurobiol ISSN: 0301-0082 Impact factor: 11.685